Clinic and animal studies demonstrated that oral-administrated berberine had distinct lipid-lowering effect. However, pharmacokinetic studies showed berberine was poorly absorbed into the body so that the levels of berberine in the blood and target tissues were far below the effective concentrations revealed. To probe the underlying mechanism, the effect of berberine on biological system was studied on a high-fat-diet-induced hamster hyperlipidemia model. Our results showed that intragastric-administered berberine was poorly absorbed into circulation and most berberine accumulated in gut content. Although the bioavailability for intragastric-administered berberine was much lower than that of intraperitoneal-administered berberine, it had stronger lipid-lowing effect, indicating gastrointestinal is a potential target for hypolipidemic effect of berberine.
Abstract
Clinic and animal studies demonstrated that oral-administrated berberine had distinct lipid-lowering effect. However, pharmacokinetic studies showed berberine was poorly absorbed into the body so that the levels of berberine in the blood and target tissues were far below the effective concentrations revealed. To probe the underlying mechanism, the effect of berberine on biological system was studied on a high-fat-diet-induced hamster hyperlipidemia model. Our results showed that intragastric-administered berberine was poorly absorbed into circulation and most berberine accumulated in gut content. Although the bioavailability for intragastric-administered berberine was much lower than that of intraperitoneal-administered berberine, it had stronger lipid-lowing effect, indicating gastrointestinal is a potential target for hypolipidemic effect of berberine.
Metabolomic study on both serum and gut content showed that oral-administrated berberine significantly regulated molecules involved in lipid metabolism, and increased the generation of bile acids in the hyperlipidemic model. DNA analysis revealed that the oral-administered berberine modulated the gut microbiota, and BBR showed a significant inhibition on the 7-dehydroxylation conversion of cholic acid to deoxycholic acid, indicating a decreased elimination of bile acids in the gut.
However, in model hamsters, elevated bile acids failed to down-regulate the expression and function of CYP7A1 in a negative feed-back way. It was suggested that the hypocholesterolemic effect for oral-administrated berberine is involved in its effect on modulating the turnover of bile acids and farnesoid X receptor signal pathway.
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Introduction
Berberine, a botanical alkaloid originally isolated from the Chinese herb Coptis chinensis, is known to possess antimicrobial activity directed against bacteria, viruses, fungi, protozoans, and helminthes. It has been widely used as an antimicrobial drug to treat gastrointestinal infections in many Asian countries [1] [2] [3] [4] [5] . Recent studies have demonstrated that berberine also exerts a lipid-lowering effect by activating an AMP-activated protein kinase signaling pathway and increasing low-density lipoprotein (LDL) receptor expression in the liver 3, [5] [6] [7] . However, pharmacokinetic studies have shown that berberine is poorly absorbed through the gut epithelium [8] [9] [10] , and the levels of berberine in the blood and target tissues are far below the effective concentrations used in in vitro cell culture studies. In detail, various studies of berberine either on rats, or mice, or pigs, or hamsters, at any doses (from 45 to 2500 mg/kg) revealed that the maximum concentration of berberine in serum/plasma was no more than 30 ng/ml (mostly average at 15 ng/mL) and less than 100 ng/ml in liver 10, 11 ; while none of the mechanism studies on in vitro cells suggested that the effective level was less than 2500 ng/ml (2500-25000ng/mL) [5] [6] [7] . Therefore, the current mechanistic hypotheses used to explain the lipid-lowering effect of berberine are insufficient to explain the results of in vivo animal studies and clinical studies orally given with berberine.
Since oral administration of berberine had poor bioavailability, and little of berberine was absorbed into the body, the non-absorbed berberine reserves in the gut.
The accumulated berberine in the gut may inevitably affect the physiology and microbiota in gut. As is well known, gut physiology and gut microbiota can not only facilitate the host's digestion and absorption of nutrients, but also affect lipid metabolism and glycolysis as well 12, 13 . The effect of berberine on lipid metabolism, gut flora and the turnover of bile acids may play an important role in elucidating the lipid lowering effect of berberine. Metabolomics provides an ideal platform to characterize metabolic patterns involved in perturbation of physiology by various stimuli, either genetic 14 , or environmental alternation, such as food 15 and xenobiotic drugs or toxins 16 , and further to explore underlying mechanism and elucidate biomarkers in different levels, such as systematic/body, local/organs and cellular levels [17] [18] [19] [20] . Considering that hamsters are an excellent hyperlipidemic model 21 , in this study, we employed metabolomics, used a high-fat diet (HFD)-induced hyperlipidemic hamster model to examine whether the lipid-lowering effect of berberine is associated with metabolism of lipids and the turnover of bile acids.
Materials and methods

Chemicals
Berberine (purity > 99%) was purchased from the National Institute for the 
Ethics Statement
All the animal experiments were performed with the approval of the Animal to acclimate them to the environment before the start of the study. The control group continued with the standard diet, whereas the high fat diet (HFD) group was fed an HFD, in which 10% coconut oil (w/w) and 0.5% cholesterol (w/w) was added to the standard diet, for two weeks to induce hyperlipidemia. Serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) levels were measured before (day 0) and after two weeks of the HFD to confirm the establishment of the hyperlipidemic model, as previously described 22 .
Treatment of hyperlipidemic hamsters with berberine
After they had been fed the HFD for two weeks, the hyperlipidemic hamsters were randomly assigned to the hyperlipidemic model control group or the berberine group. The berberine group was gavaged with berberine (100 mg/kg) daily for two weeks, and the hyperlipidemic model control and the age-matched normal control groups were given an equal volume of vehicle (0.9% saline). Body weight was recorded every two days. At the end of the treatment, the hamsters were fasted for 16
h and blood samples were collected to isolate the sera. The ceca were recovered immediately after the hamsters were killed.
For phylogenetic analysis of the gut microbiota, the contents of each intact cecum were recovered in sterile tubes, to which was added 2 mL of boiled aqueous solution containing 20% glycerol and 1.8% sodium chloride. They were then pooled according to their origins from the HFDs treated with berberine, or HFDs or the controls, respectively, and formed three groups of samples. An aliquot (50 μL) of each pooled sample was added to a tube from which the air was completely removed by a gentle stream of nitrogen. All samples of gut contents were then stored at -70 °C before analysis. For analysis of bile acids, berberine and its metabolites, the contents of each intact cecum were recovered in a sterile tube and frozen immediately (-70 °C).
Hamster gall bladder and cecum content were collected, respectively. Gall bladder was weighed, and bile acids, berberine and its metabolites in bile were determined as reported 11 . The livers were harvested for histological inspection as previously described 23 . Serum TC, TG, HDL-C, and LDL-C were determined as described 22 , using an Olympus AU2700 bichromatic autoanalyzer (Olympus, Tokyo, Japan) in Jiangsu Provincial Hospital of Traditional Chinese Medicine.
Pharmacokinetic study of berberine administered to hyperlipidemic hamsters
The hyperlipidemic hamsters were randomly divided into four treatment groups:
(1) 50 mg/kg berberine administered intragastrically (i. 
Phylogenetic analysis of the gut microbiota
The genetic diversity of the hamster intestinal microbial flora was examined in the hyperlipidemic hamsters and the berberine-treated hamsters with a culture-independent clone library 24 . DNA from the whole cecum samples was 
Metabolomic study
A well-developed metabolomic platform based on the GC/TOF-MS technique was used to profile the metabolites in the serum samples from each group, as previously reported, with a few modifications Method S1.
Effect of berberine on the cholic acid 7--dehydroxylation activity of Clostridium scindens
The 7-dehydroxylation of cholic acid is a key step in cholic acid metabolism.
Therefore, the effect of berberine on cholic acid 7-dehydroxylation was evaluated in C. scindens, a representative bacterium of the genus Clostridium in the phylum . The primary bile acids (cholic acid, 7-oxo-cholic acid) and the secondary bile acids (deoxycholic acid, allodeoxycholic acid, 3-dehydro-deoxycholic acid, 3-dehydro-allodeoxycholic acid) from each treatment were scraped from the TLC plate and quantified by liquid scintillation spectrometry.
Effect of berberine on the metabolism of cholic acid in fresh gut contents
To examine the metabolism of cholic acid, the fresh gut contents from the HFD hamsters treated with berberine (HFB), the controls treated with berberine (CB), the HFD hamsters (HF), and the controls (C) were diluted and prepared as reported ethyl acetate and the supernatant was dried. The residue was finally derivatized and analyzed in a Shimadzu QP2010 Ultra/SE (Kyoto, Japan) (Method S2).
CYP7A1 and CYP27A1 expression in HepG2 cells and hamster hepatocytes
Cholic acid is predominantly synthesized from cholesterol in the liver by two 
Statistical analysis
All the data from the biochemical analyses, pharmacokinetic experiments, and metabolomic profiling are expressed as means ± SD. One-way analysis of variance (ANOVA) was used to analyze all the data with the SPSS 16.0 software (SPSS institute, Chicago, USA).
Results
Pharmacokinetics and gastrointestinal accumulation of berberine
An established and clinically relevant hyperlipidemic hamster model was used in this study to evaluate the lipid-lowering effects of berberine and its influence on the composition of the gut microbiota 22 . Pharmacokinetic parameters, such as the AUC, the maximum concentration (C max ), and the relative bioavailability of berberine were compared between two routes of administration, intraperitoneal injection (0.5 or 2 mg/kg) and intragastric administration (50 or 200 mg/kg). As shown in Table 1 However, as compared with HFD controls, treatment with berberine (100 mg/kg, i.g.)
for two weeks significantly decreased the body weight, (157.3±5.2g vs165.4±10.4g, p=0.0129), reduced the serum TC, TG, and LDL-C levels by 47%, 45%, and 42%, respectively, Figure 1 . The HDL-C levels in the berberine group were also reduced.
Additionally, HFD induced obviously histopathologic changes in livers, which could be effectively reversed by BBR, Figure S1 .
Oral-administrated berberine regulated host metabolism and bile acids biosynthesis
To explore the effect of berberine on lipid metabolism, the hamsters' metabolic patterns were evaluated with GC/TOF-MS. Visual inspection of the total ion current chromatograms revealed obvious differences between the control (C), high-fat diet induced hamsters (HF), and HF treated with berbereine (HFB) (Figure 2) . Of the 204 peaks detected with GC/TOF-MS, 81 were authentically identified. Altogether, 62 (20 identified) peaks differentiated the hyperlipidemic model from the normal control. As shown in Table S1 , the cholesterol, free fatty acid levels and some amino acid levels were significantly elevated in the hyperlipidemic hamsters, suggesting the perturbation of their lipid metabolism and amino acid turnover. Treatment with berberine restored most of the discriminatory metabolites toward normal levels (as in the normal control) to different extents, including their fatty acids, amino acids, and cholesterol. Remarkably, as shown in Figure 2D , the serum cholic acid levels were dramatically increased in the berberine-treated hamsters (P = 0.002 vs C; P = 0.007 vs HF), suggesting that berberine modulates the bile acid metabolism.
Multivariate statistical analysis of the metabolomic data of the molecules in serum and cecal samples revealed that the hyperlipidemic model animals had distinctly different metabolic pattern from the normal controls, and oral-administrated berberine regulated metabolic pattern of the hamster model (Figure 3) . In comparison with the data from serum ( Figure 3A) , berberine showed stronger effect on deviating the metabolome in gut content ( Figure 3B ) according to the relative distance value, i.e., distance to the model group relative to the distance between model group and normal control 23 . The results were consistent with the poor bioavailability or rather low level of berberine in circulation system, and fairly efficient accumulation of berberine in gut and hence the stronger impact on gastrointestinal physiology.
Metabolic impact analysis of the data revealed that berberine significantly affect metabolism of cholesterol and/or biosynthesis of bile acids ( Figure 3C, D, Figure 4) , indicating that the turnover of bile acids was involved in lipid lowering effect of berberine.
BBR increased the total amount of bile acids in gall bladder and gut content of hamsters
Oral administration of BBR obviously increased the size and weight of the hamster gall bladder relative to the normal hamsters and the hyperlipidemic model hamsters, Table S2 , and the amounts of conjugated bile acids taurocholic aicd and glycocholic acid increased distinctly in hamster gall bladder. In gut content, the conjugated bile acids were low while and free bile acids level were much higher, Table S2 . In generally, berberine increased free bile acids in both the normal and hyperlipidemic controls, and BBR administration significantly elevated the total amount of bile acids in gall bladder and in gut content, Table S3 , indicating that berberine enhanced the metabolism of cholesterol in liver, where CYP7A1 and CYP27A1 may plays a key role in the metabolism.
The effect of berberine on the expression of CYP7A1 and CYP27A1 in hamster liver and in HepG2 cells
To investigate the effects of berberine on the upstream derivation of bile acids from cholesterol, its effects on the levels of transcription of CYP7A1 and CYP27A1 in liver of hamsters were evaluated by real-time RT-PCR. Berberine did not show significant modulation on CYP7A1, yet slightly elevated CYP27A1 expression at the mRNA level (Figure 5 A, B, p>0.05) . In HepG2 cells the levels of transcription and translation of CYP7A1 and CYP27A1 were evaluated by both real-time RT-PCR and western blotting analysis of the cognate proteins. At the levels lower than 100 ng/mL, berberine did not show distinct effect on the expression of CYP7A1 and CYP27A1.
However, at higher levels above 500 ng/mL, berberine significantly and dose-dependently increased CYP7A1 and CYP27A1 expression at both the mRNA 
Effects of berberine on the composition of the gut microbiota
By analyzing 360 16S rRNA gene sequences, we profiled the gut bacteria in the cecal samples of the three groups: HFD hamsters treated with berberine (HFB); normal control group (C), and hyperlipidemic model control group (HF). A bacterial phylogenetic tree of the hamster gut microbiota was constructed ( Figure 6A ). As shown in Figure 6B , the hamster gut microbiota was primarily composed of seven bacterial phyla: Firmicutes, Bacteroidetes, Tenericutes, Proteobacteria, Actinobacteria, Spirochetes, and Deferribacteres. This is similar to the compositions of the human and mouse gut microbiota 29 . Actinobacteria were also observed in the guts of the hyperlipidemic hamsters ( Figure   6B ). Interestingly, treatment with berberine dramatically increased the proportion of Firmicutes (from 33.09% to 50.91%), and slightly reduced the proportion of Bacteroidetes (from 34.56% to 31.82%). As a consequence, the ratio of Firmicutes to Bacteroidetes increased significantly after treatment with berberine for two weeks (1.60).
Berberine inhibited the elimination of cholic acid in C. scindens and in fresh gut contents
Berberine significantly increased the Firmicutes in the gut, and Clostridium was 
Discussion
The modulation of oral-administrated berberine on metabolites in serum and gut content and metabolic pathways involved
Local tissues/organs usually showed a different panel of metabolic markers from circulation system. In this study, although different metabolic sets were observed in serum and gut content samples after treatment with berberine, metabolic impact analysis suggested that oral administration of berberine perturbed many metabolic pathways for them (serum and gut content) in a similar way. In detail, oral administrated berberine obviously regulated glycolysis, amino acids metabolism and lipid metabolism, which is consistent with a previous study on berberine 30 . In addition to the modulation of glycolysis both in serum and gut content, which is consistent with the hypoglycemic activity of berberine 31 , to our delight, berberine showed significant effect on metabolism of cholesterol and biosynthesis of bile acids.
The decreased cholesterol in serum and increased generation of cholic acid suggested the underlying mechanism for the hypocholesterolemic effect of berberine.
In term of metabolites set and relative distance in the score plot of PLSDA models, oral-administrated berberine showed stronger effect on metabolites in gut content than those in serum, suggesting the accumulated berberine in gut and the stronger effect on gut flora and the metabolism. However, there is obvious contradiction between the substantial effect of berberine on systematic metabolism and the poor exposure of berberine in circulation system. In other words, little berberine inside the body may not show distinct effect on metabolites in serum.
Previous studies suggested that the possible reason may be attributed to the close association between gut microflora and host metabolism that has been well documented 20, 32 . This might be the right reason why metabolic pathways perturbed by berberine elucidated by serum metabolomics are closely associated with the effect of berberine on gut microbiota and the associated metabolism.
Gastrointestinal accumulation and lipid lowering effect of oral-administrated berberine
Previous studies have shown that berberine affects the lipid metabolism by activating AMPK signal pathway and low-density lipoprotein (LDL) receptor 3, 5-7 .
However, the cellular mechanisms proposed by several in vitro studies do not appropriately explain the in vivo lipid-lowering effects of berberine because the bioavailability of orally administered berberine is extremely low. Our pharmacokinetic study has confirmed that little berberine is absorbed into the body after its oral administration. The maximum serum levels of berberine after its oral administration of hamsters at doses of 50 and 200 mg/kg were 3.2 ± 0.9 and 8.0 ± 3.3 ng/mL, respectively. The amount of berberine used in all the reported in vitro studies was much higher than could be achieved by its oral administration (around 1000 times). Although the bioavailability of berberine after its oral administration was much lower than after its i.g. administration (based on AUC and C max ), it exerted better hypolipidemic effects, as indicated by the greater reductions in serum TC, TG, and LDL-C levels than were achieved with an intraperitoneal injection, which produced much higher AUC and C max values ( Table 1 ). Considering that a large amount of berberine reserved in gastrointestinal tract while serum berberine was rather low, it is presumed that the lipid-lowering effect of oral-administrated berberine was involved in the modulation of gastrointestinal physiology.
Effects of berberine on the turnover of bile acids
The data clearly showed that berberine significantly increased the generation of bile acids (Table S2, S3) . While the elimination of cholic acid, primarily via 7-dehydroxylation of cholic acid 27 , was significantly inhibited (Figure 7) , in a C.
scindens, which is the predominant bacterium in the gut Firmicutes in both animals and humans 33, 34 . A further in vitro study of the metabolism of cholic acid in fresh gut contents also showed that berberine significantly reduced the catabolism of cholic acid by the gut flora collected from both the HFD hamsters and the controls ( Figure   7C ). In general, berberine increased the net gain of bile acids.
Effects of berberine on the biosynthesis of bile acids
Both berberine and bile acids may have effect on the metabolism of cholesterol,
i.e., the expression and function of CYP7A1, CYP27A1. In vitro data showed that, in
HepG2 cells, high concentration (above 500 ng/ml) of berberine significantly increased CYP7A1 and CYP27A1 expression at both the mRNA ( Figure 5 C, D) and protein levels, while lower level (no more than 100 ng/ml) berberine showed little effect. Therefore, high level of berberine in hamster will up-regulate CYP7A1 and CYP27A1, while low level of berberine in hamster ought to show little effect on CYP7A1 and CYP27A1. In consistent with the rather low exposure of berberine in hamster liver, hepatic CYP7A1 and CYP27A1 in hamsters were not significantly affected after oral administration of berberine. Consequently, the direct effect of berberine on CYP7A1, CYP27A1 was thus out of the question.
Bile acids are the end products of the catabolism of cholesterol in liver, primarily via two processes regulated by two key enzymes, CYP7A1 and CYP27A1 35, 36 . It has been well established that cholesterol 7a-hydroxylase (CYP7A1), a microsomal cytochrome p450 enzyme, dominates the first and rate-limiting step of cholesterol catabolism, and CYP7A1 gene is modulated by bile acids through nuclear receptor farnesoid X receptor (FXR) signal pathway 37 . As the end products of cholesterol metabolism, bile acids play a key role in cholesterol homeostasis. An up-regulated CYP7A1 can lead to higher level of bile acids to favor the hypolipidemic effect by facilitating conjugation with and the excretion of lipids 38, 39 . Simultaneously, the elevated bile acids usually inhibit the catabolism of cholesterol in a negative feedback way by promoting hepatic and intestinal FXR signal pathways to depress CYP7A1 expression and function 
Lipid lowering effect of berberine and the composition of gut microbiota.
Host-microbe interactions are essential to many aspects of the mammalian physiology, ranging from metabolic activity to immune homeostasis 40 . In this regard, the gut microbiota can be considered a "microbial organ" within the host organism 41 .
Recent studies have suggested that the gut microbiota not only facilitates the host's digestion and absorption of nutrients, but also affects the host's energy balance by regulating lipid metabolism and glycolysis. Aberrations in the gut microbiota contribute to the development of diverse human diseases, including diabetes, obesity, fatty liver diseases, inflammatory bowel diseases, and cancers 1, 42, 43 .
It has been reported that the relative proportion of Bacteroidetes is lower in both obese people and obese mice than in lean people and lean mice 44, 45 . Ley et al. found
that the relative abundances of Firmicutes and Bacteroidetes in obese people changed as they lost weight on a fat-restricted or a carbohydrate-restricted low-calorie diet 46 .
Interestingly, this phenomenon was also observed in children in the rural African village of Burkina Faso, where the high-fiber diet is similar to that of early human settlements at the time of the beginning of agriculture 47 . These studies suggest the both Bacteroidetes and Firmicutes play important roles in the host metabolism.
However, in this study, we found that in the normal hamster controls, the gut microbial community was dominated by Firmicutes and a high-fat diet induced an increase in Bacteroidetes and a reduction in Firmicutes in the hyperlipidemic hamsters.
Treatment with berberine reversed the Bacteroidetes/Firmicutes ratio, and restored the Firmicutes to the role of the absolutely dominant bacteria. These results suggest that the Firmicutes play a critical role in the lipid metabolism of the host. The discrepancy in the gut Bacteroidetes/Firmicutes ratio between humans, mice, and hamsters might be attributable to variations in the overall gut environments and genetic differences between the hosts.
Additionally, different species of bacteria isolated from the human gastrointestinal tract show different bile salt hydrolase (BSH) activities 48 . Among the gut microbiota, the phylum Firmicutes has been shown to have higher BSH activity than the phylum Bacteroidetes, which is only active for tauro-conjugated bile acid 49 .
Our study clearly shows that berberine significantly increased the Firmicutes/Bacteroidetes ratio, suggesting that this is one of the mechanisms underlying the berberine-induced increase in free serum cholic acid and the lipid-lowering effect of berberine. Although we did not evaluate BSH activity in this study, we believe the increase in Firmicutes and BSH activity is involved in the elevation of cholic acid, although further studies are required to clarify the effect of berberine on BSH activity.
Conclusion remarks
Our data showed that intragastric-administered berberine was poorly absorbed into circulation and most berberine accumulated in gut content. The accumulated berberine in gut strongly affected the metabolites in gut and hence the metabolites in circulation system, although level of berberine was rather low in hamster serum. The obvious modulation of lipid metabolism and glycolysis suggested the hypolipidemic and hypoglycemic effect of berberine. The reduced cholesterol in serum and elevated generation of bile acids in gall bladder and gut content of hamsters suggested that the lipid-lowering effect of berberine is involved in metabolism of cholesterol and biosynthesis of bile acids. Since elevated bile acids failed to down-regulate the expression and function of CYP7A1 in a negative feed-back way, it was suggested that the hypocholesterolemic effect for oral-administrated berberine is primarily Data are means ±SD (n = 5). Statistical significance relative to HF group, *p<0.05, * *P<0.01. Values are mean ± SD (n = 5). Statistical significance was evaluated using one-way ANOVA. BBR, berberine; HF, the HFD hamsters; C, the controls; HF+BBR, HFD hamsters treated with BBR (100 mg/kg); C+BBR, the controls treated with berberine(100 mg/kg). Values are mean ± SD of three independent experiments and analyzed using one-way ANOVA,* P<0.05, * *P<0.01, relative to their controls, respectively.
